Member Info for Hurst10

In the press this week.

Affyxell a nil cost asset for Avacta, valuation going north.

"The Novo Nordisk Foundation, the philanthropic fund behind the maker of blockbuster drugs Ozempic and Wegovy, will give more donations to stem-cell based therapies as part of a shift in its focus areas.

The fund, which has total assets of more than USD 80bn at a group level, will make regenerative medicine an “explicit part” of its strategy, according to a statement on Tuesday. The foundation reached USD 1.1bn in grants last year."

https://*********************/companies/uk/other/avacta-group-plc/research/trinity-delta/avacta-data-and-clinical-progress-validate-pre-cision-platform/33_c91687bb-d808-4749-b299-6bd74592852a

As you can see from Novartis upcoming conferences,

the company and the sector has a busy rest of the month,

closing with JP Morgan in London.

Plenty of Precision Medicine to discuss!

June 06, 2024 - Jefferies Global Healthcare Conference

New York, USA

June 11, 2024 - Goldman Sachs Global Healthcare Conference

Miami, USA

June 19, 2024 - Citi European Healthcare Conference

London, UK

June 20, 2024 - J.P. Morgan European Healthcare Conference

London, UK

Page 23 :

"significantly widens the Therapeutic index of Doxorubicin!"

How big is the above description?

With Ely Lilly and Norvartis both buying,the sector should have an interesting 2nd half of the year.

For the sector.

A precision conclusion .

Meanwhile Jefferies healthcare conference later this week.

Monday, June 3 Time: 9:30 AM-10:30 AM Title: PSMA-Targeted Radioligand Therapy in mCRPC: A Precision Approach Description: Mark Fallick, MD, will discuss the clinical data and safety profile of a prescription treatment for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Company: Novartis Presenter: Mark Fallick, MD, MBA, FACS, Senior Medical Director, Prostate Radioligand Therapy, Novartis

Of the 10 largest Series A rounds this year, six are biotechs. This includes the largest financing, which went to Xaira Therapeutics, a San Francisco-based startup using AI for drug discovery and development. The company secured more than $1 billion of committed capital in April from lead investors Arch Venture Partners and Foresite Capital.

Novartis etc have said that Precision Medicine is the future.

With regards to Avacta therapeutic, who gets there first?

Private equity or US investment bank for IPO?

The second-largest Series A also went to a biotech, Mirador Therapeutics, which is focused on precision medicine for chronic inflammation and fibrotic disease. The San Diego company landed $400 million in a March round, also led by Arch.

The presence of private equity at ASCO this year will be substantial and very much something the majors are aware of.

An Activist long only fund could easily join the shareholder list ( might be doing that already ) and make it much more expensive for the likes of Novartis etc to strike a deal.

PI's should take advantage of the ridiculous low valuation.

Anyway up to you

This year at ASCO we will see Private Equity taking advantage

Of the fast growing interest in the Radiotherapy area,Avacta now working with Eli Lilly( Point) and Novartis etc. stepping up the pace on the M&A front, would expect plenty of news in the near future.

Furthermore, Q1 2024 saw increased investor interest in antibody-drug conjugates (ADCs) and radiopharmaceuticals. Venture financing for ADCs saw a more than fivefold increase, surging from $98 million to $568 million from Q4 2023 to Q1 2024. Notably, the largest venture financing deal reported in Q1 2024 was Tubulis, a biotech company headquartered in Germany, which secured $139 million in Series B2 funding to support the clinical evaluation of its next-generation ADC lead candidates, TUB-040, targeting ovarian and lung cancers, and TUB-030, targeting solid tumours. Similarly, innovative radiopharmaceuticals are positioned for sustained growth, with venture capital investment surging more than 330% in Q1 2024 compared to the same quarter of the previous year.

Makes current price level of AVCT looking absurd.

The company could risk being taking private prior to a NYSE listing.

Look at the comp chart.

Dr.Martens figures today vs Birkenstock climbing back to IPO levels.

Stock clearly could be a M&A tatget

Birkenstock (BIRK.N), opens new tab raised its annual revenue and core profit forecasts on Thursday as the German sandal maker bets on full-price selling and strong demand for its cork-based sandals and newer closed-toe styles, sending its shares up 10% premarket.

House broker ???

do not think so.

Amazing program!

https://conferences.asco.org/am/program

Asahi Kasei (3407.T), opens new tab offered to buy Swedish drugmaker Calliditas Therapeutics (CALTX.ST), opens new tab for around $1.1 billion on Tuesday as the Japanese maker company looks to turn itself into a global player in pharmaceuticals.

Asahi Kasei said it would offer about 11.8 billion Swedish crowns ($1.1 billion) for Stockholm-based Calliditas, in a deal approved by the boards of both companies. The offer of 208 crowns per share represents an 83% premium on Calliditas' closing price of 113.6 crowns on Monday.

The usual suspects very much will be on the bid next week.

Flow of RNS and ASCO M&A, will keep the sector busy as ever!

In front of ASCO, perhaps worth reminding ourselves,

Precision medicine currently est to be worth $80bill and is now est . to be worth $160bill by 2032.

Plenty of work for Avacta Therapeutics inc. post Nasdaq listing.

And they will all ( incl. Novartis ) be at ASCO!

Merck to acquire Mirus Bio for $600m.

Another transaction pre ASCO !

With ASCO around the corner, not surprising that we are seeing an acceleration of newsflow in the field of precision oncology and one would expect next week many more M&A related headlines by the majors in the field of Precision Medicine. Avacta's well timed RNS of today, should be followed up with first of several license deals. Dr. William Tap will also be making more headlines from the ongoing two week trials.

Novartis will be in a hurry to secure a deal!

Https://www.fiercehealthcare.com/health-tech/precision-medicine-company-tempus-ai-files-go-public